about
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavirEffect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir.Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy.Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapyIf taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trialPharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.Dual protease inhibitor therapy in the management of the HIV-1.Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.Role of therapeutic drug monitoring for protease inhibitors.Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.Clinical pharmacology and pharmacokinetics of amprenavir.A critical evaluation of the therapeutic range of indinavir.Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.Development of indinavir submicron lipid emulsions loaded with lipoamino acids-in vivo pharmacokinetics and brain-specific delivery.Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.Early factors in successful anti-HIV treatment.The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjectsTherapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapyEffect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.High variability of plasma drug concentrations in dual protease inhibitor regimens.Use of saliva specimens for monitoring indinavir therapy in human immunodeficiency virus-infected patients.Pharmacokinetic properties of indinavir in rat: some limitations of noncompartmental analysis.Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.Variability in activity of hepatic CYP3A4 in patients infected with HIV.Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine.Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.No residual activity of raltegravir after development of 148 complex mutations in vivo.GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
P2860
Q28345258-F793E963-B54D-4B32-B856-B8E84AFE46C5Q33555851-E0D3542F-96C8-43C1-848F-EB0EAC06DA44Q33946915-9C087E70-0352-4A2A-9FC2-F4266E9D3E08Q33954823-996143B4-6479-4904-B9EF-919C07ED7DDDQ33979204-36DB16A9-71D5-4F00-9F49-9AFF84CB490CQ33981246-EB2585C0-CA88-49A0-9BF4-473C669AF30AQ34103495-6329E824-C228-4085-9CB1-64C7CCEEF044Q34113462-4F12484F-B822-4A56-9FBB-AFB506954D41Q34181804-786A355D-735D-45F2-A983-6AE54B740C45Q34253139-72401117-FDAC-4E6F-8B88-6D66FEBDDBB6Q34284286-3A17A73D-83AE-49E5-8ED1-D27959B2FDC5Q34394720-7C0BAD08-2707-4CA8-B1FD-A9694138A2FCQ34509359-53043CEB-5019-4328-9669-B332974F654AQ34709881-D51A9CC2-473D-47CE-8B75-20179D34038DQ34720072-0E62F099-2370-472B-BB33-FC2934A568E5Q34733900-33A4BC42-5F8E-4BC2-BF6F-95FEB08DC042Q35195035-21CF061D-E80B-449B-BFC1-FCF993B16FA1Q35207282-236E35E6-5926-4D10-B32B-86F7E3BA60BCQ35804001-648FB8DF-B5DE-4143-8BA8-CBDB0D7C5FACQ35826064-32992129-6A48-4EC2-8D63-BE7807142A77Q36489794-E0E3C90A-D337-4B70-B38E-429B0E7CC69BQ37352380-4DEE6FE0-C6B2-4FEB-B09F-6ED54B1FED2FQ37378110-6E330691-1089-4E73-A107-C2378E45C915Q37383940-CBEBA0C8-93AA-4BAC-8BA4-11C2E84BB371Q37489345-E605E385-E5FA-4B86-9592-32A0BC6405D9Q37598680-017C3E0B-6791-4DE0-BEA1-62A4DADC18E3Q38980548-77ADE4C2-287B-4BD4-A093-D5D9623245DFQ39035831-317FF419-B4F4-4029-85FD-DA78BFA2F84DQ39475101-51F57AC9-36C9-430F-B9C4-B685315FCC08Q43282509-9B9362AC-62DC-4DF1-ACBC-971221004E66Q43576837-A52EA3FD-2B83-42D2-AAA1-855003FE09B2Q44087054-D658C4AD-2E47-428D-8027-3AEE3353E62DQ44183256-D7AE240B-FA43-4C00-B9DF-9616BAA230A5Q44874904-627B59D8-EB3C-488C-92BD-CB3E720BCA92Q44909192-CA567BF3-6448-4AD1-A705-BC8CF8B0B158Q45090413-E5589E50-7800-4892-AFD1-39555DB748BAQ45117171-88117813-EBCA-4A63-8BEB-63392DDA3BCDQ46151088-6A392164-9595-482E-BF5D-6CA829D0FA9BQ53885340-F2632221-8353-44DF-990D-2227F2C08C2B
P2860
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Indinavir concentrations and antiviral effect.
@en
Indinavir concentrations and antiviral effect.
@nl
type
label
Indinavir concentrations and antiviral effect.
@en
Indinavir concentrations and antiviral effect.
@nl
prefLabel
Indinavir concentrations and antiviral effect.
@en
Indinavir concentrations and antiviral effect.
@nl
P2093
P2860
P1433
P1476
Indinavir concentrations and antiviral effect.
@en
P2093
P2860
P304
P356
10.1592/PHCO.19.9.708.31544
P407
P577
1999-06-01T00:00:00Z